ChemotherapyFDA-approvedFirst-line
Xeloda
Generic name: capecitabine
How it works
Converted into 5-fluorouracil, a chemotherapy agent that interferes with DNA replication in cancer cells, causing cell death.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, Xeloda monotherapy improved median overall survival by approximately 2 months compared to best supportive care.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Study Examines Effectiveness of Capecitabine in Triple-Negative Breast Cancer | Breast Cancer | observational | Adjuvant capecitabine did not improve disease-free survival (HR = 0.96; 95% CI 0.52-1.78) or overall survival (HR = 0.70; 95% CI 0.33-1.46) in univariable analyses. | Source → |
| Genetic Testing for Breast Cancer Patients on Capecitabine May Be Cost-Effective | Breast Cancer | phase-3 | The genotyping strategy yielded 1.16 QALYs at a cost of $2,832, compared to $2,677 and 1.15 QALYs for the no-genotyping strategy. | Source → |
| New Treatment Combination for Triple-Negative Breast Cancer Being Tested | Breast Cancer | phase-3 | — | Source → |
| Testing Tetrathiomolybdate and Capecitabine for Triple Negative Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Methylcobalamin May Help Prevent Hand-Foot Syndrome in Breast Cancer Patients | Breast Cancer | phase-3 | Grade ≥2 hand-foot syndrome occurred in 14.5% of patients in the methylcobalamin group, compared to 29.1% in the placebo group. | Source → |
| Capecitabine plus Temozolomide Therapy for Pancreatic Tumors | Pancreatic Cancer | observational | The objective response rates and disease control rates were 26.7 and 66.7%, respectively. | Source → |
| Predicting Capecitabine-Induced Diarrhea in Cancer Patients | Colorectal Cancer | lab-study | The area under curve of the model was 0.907, with a specificity of 100.0% and a sensitivity of 71.4% for predicting diarrhea in colorectal cancer patients. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.